SMO mutations confer poor prognosis in malignant pleural mesothelioma

BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive tumor but approximately 12% of patients survive more than 3 years. The biological differences underlying better outcomes are not known. Several targeted agents and immunotherapy have been ineffective. Hedgehog (Hh) is one emerging pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Signorelli, Diego, Proto, Claudia, Botta, Laura, Trama, Annalisa, Tiseo, Marcello, Pasello, Giulia, Lo Russo, Giuseppe, Fabbri, Alessandra, Imbimbo, Martina, Busico, Adele, Prelaj, Arsela, Ferrara, Roberto, Galli, Giulia, De Toma, Alessandro, Tamborini, Elena, Pastorino, Ugo, de Braud, Filippo, Gatta, Gemma, Garassino, Marina Chiara, Ganzinelli, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653142/
https://www.ncbi.nlm.nih.gov/pubmed/33209614
http://dx.doi.org/10.21037/tlcr-19-425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653142/
https://www.ncbi.nlm.nih.gov/pubmed/33209614
http://dx.doi.org/10.21037/tlcr-19-425

Ejemplares similares